Optimal design of clinical trials with biologics using dose-time-response models.
Biologics, in particular monoclonal antibodies, are important therapies in serious diseases such as cancer, psoriasis, multiple sclerosis, or rheumatoid arthritis. While most conventional drugs are given daily, the effect of monoclonal antibodies often lasts for months, and hence, these biologics re...
| Publicado en: | Statistics in Medicine Vol. 33; no. 30; pp. 5249 - 5265 |
|---|---|
| Autores principales: | , |
| Formato: | research Journal Article |
| Publicado: |
Wiley-Blackwell
Dec2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |